| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.03 | 2.8% |
| Total Income | 1.03 | 2.8% |
| Expenditure | 8.15 | 77.2% |
| PBT | — | |
| Net Profit | -6.95 | 60.1% |
| OPM | — | |
| NPM | — | |
| EPS | -1.05 | 11.8% |
Plus Therapeutics Reports Q1 2026 Financial Results
16 May 2026 · 16 May, 1:57 am
Summary
Plus Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The company reported a cash and investments balance of $15.1 million. Revenue for the quarter was $1.0 million, including grant revenue and CNSide diagnostic billings. The total operating loss was $7.1 million, and the net loss was $6.9 million, or $1.05 per basic share. The company reaffirmed its anticipated milestones and outlook for 2026.
Key Highlights
- 1
Plus Therapeutics reported a cash and investments balance of $15.1 million as of March 31, 2026, compared to $8.6 million as of December 31, 2025.
- 2
The company recognized $1.0 million in revenue in the first quarter of 2026, including grant revenue from CPRIT and CNSide diagnostic billings.
- 3
Total operating loss for the first quarter of 2026 was $7.1 million, compared to $3.5 million for the first quarter of 2025.
- 4
Net loss for the first quarter of 2026 was $6.9 million, or $1.05 per basic share, compared to $17.4 million, or $29.86 per basic share, for the first quarter of 2025.
- 5
The company completed an upsized public offering generating $15 million in gross proceeds, increasing the available cash balance.
- 6
Payer coverage agreements increased total U.S. covered lives to approximately 81 million with the addition of Blue Shield of California.
Management Comments
Marc H. Hedrick
M.D.
"Our team remains focused on our two highest-priority 2026 goals, CNSide commercial scale-up and REYOBIQ pivotal-trial readiness," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "We continue to add payers for CNSide, including a fourth national payer, expanding coverage to approximately 81 million covered lives, as well as receiving a unique PLA code for billing and successfully enrolling CNSide with Medicare. Concurrently, we secured FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, while progressing on the ReSPECT-LM clinical trial. We enter the second quarter with the resources and focus to continue to deliver on our 2026 milestones."
Informational and educational content only. Not investment advice.